Yuliya Fedorchenko,Olena Zimba
Yuliya Fedorchenko
Consequences of Corona Virus Disease-19 (COVID-19) in patients with rheumatic diseases (RDs) are clinically diverse. SARS-CoV-2 infection has been associated with various autoimmune and rheumatic manifestations over the past three years. Em...
Unauthorized change of immunosuppressants by patients with rheumatic diseases in the COVID-19 pandemic: a cross-sectional analysis of a patient survey [0.03%]
新型冠状病毒肺炎大流行期间风湿性疾病患者未经许可更改免疫抑制剂的跨境分析：基于患者的调查研究
Simon Dahm,Joerg C Henes,Sebastian J Saur
Simon Dahm
This study provides insight in behavior and perspective of rheumatic patients during the first COVID-19 wave. Especially, we analyzed the patients' fear of COVID-19 and unauthorized change of immunosuppressive medication in consequence of t...
Systemic juvenile idiopathic arthritis: frequency and long-term outcome in Western Australia [0.03%]
系统性幼年特发性关节炎：西澳大利亚的患病率及长期预后
Johannes C Nossent,Erin Kelty,Helen Keen et al.
Johannes C Nossent et al.
Systemic juvenile idiopathic arthritis (S-JIA) is a rare but potentially life threatening autoinflammatory condition of childhood. Given the limited data on S-JIA from the Australasian region, we investigated the epidemiological characteris...
Biopsychosocial factors should be considered when evaluating central sensitization in axial spondyloarthritis [0.03%]
在评估轴向脊柱关节炎的中枢敏化时应考虑生物心理社会因素
Aylin Sariyildiz,Ilke Coskun Benlidayi,Ipek Turk et al.
Aylin Sariyildiz et al.
To identify the determinants of central sensitization (CS) in patients with axial spondyloarthritis (axSpA). Central Sensitization Inventory (CSI) was used to determine CS frequency. Disease-related variables including Bath Ankylosing Spond...
Comparison between methotrexate and apremilast in Psoriatic Arthritis-a single blind randomized controlled trial (APREMEPsA study) [0.03%]
甲氨蝶呤与阿普利玛斯特治疗银屑病关节炎的比较：单盲随机对照试验（APREMEPsA研究）
Joydeep Samanta,Gsrsnk Naidu,Arghya Chattopadhyay et al.
Joydeep Samanta et al.
To compare the efficacy of methotrexate and apremilast in psoriatic arthritis (PsA). This Single blinded (physician), parallel group, randomized controlled trial was conducted at a single centre between October 2019 and December 2020. Adult...
Randomized Controlled Trial
Rheumatology international. 2023 May;43(5):841-848. DOI:10.1007/s00296-023-05315-4 2023
Cardiac dysfunction in mixed connective tissue disease: a nationwide observational study [0.03%]
混合性结缔组织病的心脏功能障碍：一项全国观察研究
Simon Girmai Berger,Birgit Nomeland Witczak,Silje Reiseter et al.
Simon Girmai Berger et al.
We aimed to identify cardiac function in patients with established mixed connective tissue disease (MCTD). This was a cross-sectional case-control study of well-characterised MCTD patients who had previously been included in a nationwide co...
Observational Study
Rheumatology international. 2023 Jun;43(6):1055-1065. DOI:10.1007/s00296-023-05308-3 2023
Long-term persistence of oral methotrexate and associated factors in rheumatoid arthritis: a retrospective cohort study [0.03%]
口服甲氨蝶呤的长期维持及影响因素在类风湿关节炎患者中的回顾性队列研究
Varun Dhir,Chandra Bhushan Prasad,Sandeep Kumar et al.
Varun Dhir et al.
There is little data on long-term persistence/continuation of methotrexate among Indian Rheumatoid arthritis patients. We assembled a retrospective single-center cohort consisting of RA patients (fulfilling 1987 ACR criteria) started on met...
Rituximab as the first-line therapy in anti-synthetase syndrome-related interstitial lung disease [0.03%]
利妥昔单抗作为合成酶综合征相关间质性肺病的一线治疗药物
Tatjana Zekić
Tatjana Zekić
Anti-synthetase syndrome (ASS) is an idiopathic inflammatory myopathy (IIM). In comparison to interstitial lung disease (ILD) in polymyositis and dermatomyositis (PM/DM), ILD in ASS is more frequent, has a more aggressive phenotype, a great...
Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab [0.03%]
利妥昔单抗类似药GP2013治疗类风湿关节炎初治或由原研利妥昔单抗转换而来的患者中的真实世界经验
Katarzyna Łosińska,Mariusz Korkosz,Are Hugo Pripp et al.
Katarzyna Łosińska et al.
Randomized controlled trials showed high comparability of biosimilar rituximab (bs-RTX) GP2013 to biologic originator RTX (bo-RTX). Data on effectiveness of switching from bo-RTX to bs-RTX, starting therapy with bs-RTX, and bs-RTX drug surv...
Observational Study
Rheumatology international. 2023 May;43(5):881-888. DOI:10.1007/s00296-023-05307-4 2023
The role of liver transaminase levels in methotrexate intolerance in juvenile idiopathic arthritis-a cross-sectional study [0.03%]
儿童特发性关节炎甲氨蝶呤不耐受的肝脏转氨酶水平的作用-一项回顾性研究
Camilla Wibrand,Nini Kyvsgaard,Anne Estmann Christensen et al.
Camilla Wibrand et al.
Methotrexate (MTX) plays a key role when treating juvenile idiopathic arthritis (JIA), but MTX-intolerance is challenging. MTX-treatment might affect the liver, causing elevated levels of alanine aminotransferase (ALT), yet the role of ALT-...